SRX Global Agrees to Buy Cell Therapy Developer CERo Therapeutics
A special purpose vehicle, CERO 1236, will raise money directly into the subsidiary so existing SRX shareholders are not diluted, the company said.
By Bootstrapped Wealth Money Desk
· 1 min read
SRX Global Inc. said on October 7, 2026 that it signed a definitive purchase agreement to acquire CERo Therapeutics, a cell therapy developer, which would become a wholly owned unit of SRX. The buyer is working with CERO 1236, a special purpose vehicle it wholly owns, according to a statement distributed by GlobeNewswire.
SRX, based in North Palm Beach, Fla., trades on NYSE American under SRXH and describes itself as an AI-enabled investment platform. The target is the operating business of CERo Therapeutics Holdings Inc., which trades on the OTCQB market under CERO.
The SPV is to raise capital directly into the subsidiary rather than issuing shares that would dilute current SRX holders, the company said. Kent Cunningham, chief executive of SRX, said the deal fits a strategy of backing "high-conviction operating companies" and would widen CERo's access to funding.
Andrew Kucharchuk, CERo's finance chief, is expected to become president of CERo Therapeutics after closing. Chief Executive Chris Ehrlich and director Brian Atwood are expected to join the unit's board as special advisers.
CERo has treated six patients in its Phase 1 CERTAIN-T study of CER-1236 for blood cancers, with no dose-limiting toxicities reported in the most recent three-patient group. A third cohort is screening patients. Completion depends on closing conditions and a go-shop process.
This story was first reported by GlobeNewswire (Small Business News).
Comments